SPECIAL REPORT | The way South Australians design their communities and their homes must change, planners warn, with the impacts of climate change a present reality. Stephanie Richards reports on how the state has been preparing its built form – and what needs to happen next.
As Adelaide swelters through an uncomfortable spate of record-breaking heat and dryness, the need for cooler, better-insulated buildings and shadier streets is more pressing than ever before.
The number of days reaching over 40 degrees in Adelaide has more than doubled in the past 10 years, with the Bureau of Meteorology forecasting maximum daily temperatures for South Australia will rise by between 1 and 2.1 degrees by 2050.
But a temperature rise is just one part of South Australia's climate outlook. According to the Environment Protection Authority, South Australian coasts have seen a sea level rise of 1.5-4mm each year since 1965. The EPA projects those levels to rise by about one metre by 2100.
Sea level rise is particularly concerning given the majority of South Australian towns are located within 50km of the coast. According to the EPA, more than 80 per cent of South Australians live within Greater Adelaide – much of which is a low-lying coastal area which the EPA says is vulnerable to sea-level rise and storm surge.
"Climate change is definitely something that people need to consider when thinking about planning decisions or building houses," Adelaide Sustainable Building Network chair Ken Long said.
"We can't just keep on designing as we've done before, because that's just either going to get more expensive or it's just simply not going to work.
Long, a sustainability consultant who has advised on major building projects including Adelaide Airport and Lot 14 at the old Royal Adelaide Hospital site, said the SA planning industry has evolved to a point where it now considers climate projections in most building decisions.
His warning on climate change adaptation foreshadows a costly reality projected for South Australia's coastline.
In 2011, a Federal Government report estimated that between 31,000 and 48,000 residential buildings in South Australia might be at risk of flooding from a sea level rise of 1.1 metres.
The study, which did not take into consideration existing coastal protection such as seawalls, also estimated that a sea level rise of 1.1 metres would put about 6700 km of roads, 200 km of railways, 1100 light industrial buildings and 1500 commercial buildings at risk in South Australia.
The replacement value, according to the report, was estimated at about $5-8 billion for at-risk homes, $22-27 billion for commercial buildings, $7 billion for roads and $0.6-1.3 billion for railways.
University of Adelaide Professor of Planning, Jon Kellett, said water inundation has already caused havoc for properties at Middle Beach, a small coastal town north of Adelaide.
"Middle Beach is already flooding frequently and is in a sense past the point of no return," he said.
But Kellett said it's not just the rural areas that will bear the brunt of climate change, with metropolitan Adelaide also set to lose "an enormous amount of investment" on the coast.
"What is incontrovertible is that we've got monitoring data… which shows that every year since the mid-1990s we've seen about three millimetres of rise in sea levels," he said.
"It doesn't sound like much but as the decades roll by that amounts up and when you get a storm event with a surge, places that didn't use to get flooded will become under threat.
"In metropolitan Adelaide, I'm not just talking about the individual houses, but commercial developments, shipyards, docks, all those kinds of infrastructure.
Kellett said the waste water treatment plant at Lonsdale is an example of a low-lying building at risk of flooding.
"Over time it will be threatened by flooding and erosion because of its low location," he said.
"It's releasing cleaned-up water into the sea and eventually it will have nowhere to go.
"This is something long-term – we're talking decades, usually. But, the nature of planning is, we have to be thinking of these things now.
It's not just flooding that has caused problems for Adelaide's existing infrastructure.
Long said a lack of foresight from past architects has meant most of Adelaide's coastal properties are ill-equipped to deal with soaring temperatures.
"When you look at coastal properties it's quite interesting because the majority of Adelaide's coast is to the west, which receives the harshest sun," he said.
"We've got a lot of properties that are facing west that are just boiling in the summer, so people are cranking the air-conditioner which is adding stress to the (energy) grid.
Long said past planning decisions had also impacted South Australia's ability to effectively deal with rainwater flow.
"We need more water-sensitive design, especially given scientists say torrential rainfall will come more and we have less pervious surfaces," he said.
"At the moment Adelaide has been engineered to just get rid of the water – get it away from the streets and roads as soon as we can – and that's why you see all these creeks that are bordered by concrete channels to channel the water to move in one direction.
"If you have waterways which are channelling water out to the sea, that's going to accelerate the water flow and it's going to get it away, but what happens when there is torrential rain?
According to Planning Institute of Australia state branch president, Kym Pryde, climate change adaptation has been on South Australia's planning radar for the past 15 years, with planners now tied to strict state and local government guidelines that determine where and how buildings are constructed.
But she said while it is important for governments to enforce sound guidelines to prevent flooding or excessive heat in new builds, those policies can also create problems for developers where levels required to meet climate change projections are above already developed areas..
"We don't want people's houses to be subject to flooding or storm surge inundation, but it creates that problem of trying to link the old infrastructure that already exists with the new stuff that's going to be higher," she said.
Pryde said part of the problem with Australia's climate change planning policies was a disconnect between different levels of government.
She said there was a tendency at all government levels for planning responses to climate change to be adopted at a "piecemeal" rate.
"You can have all the right legislation and policies in place, but if you don't have the support from the Federal Government or the local government implementing it on the ground, then it's really difficult to get the changes in need," she said.
"Government policies on climate change are a bit piecemeal – they might apply to this area or that area, but it's not a consistent thing.
But, Pryde rated the State Government's action on climate change adaptation highly, saying South Australia's harsh climate might have provoked a more concerted effort for change than elsewhere in Australia.
"I certainly think that, from what I've seen from other states, our government has put it as a priority much more than other areas like the eastern states," she said.
"Adelaide is not developing at the same rapid rate as Sydney, Brisbane or Melbourne, so our government actually has the time to have a think about what our future might look like.
Long agreed, saying strategies such as the Adelaide City Council and State Government's Carbon Neutral Adelaide program, which aims for Adelaide to be one of the world's first carbon neutral cities by 2025, and the State Government's "30-Year Plan for Greater Adelaide", which outlines targets for Adelaide to become more "liveable, competitive and sustainable", set a benchmark for the rest of Australia.
"Once the State Government got together a couple of years ago and made those statements about wanting to be carbon neutral that lit a fire in terms of what is the identity of Adelaide," he said.
"I view Carbon Neutral Adelaide as an entrenched identity for South Australia because now it is viewed as a worldwide marketing tool.
According to Long, the challenge lies in convincing homebuilders to take up sustainability measures when designing their houses.
He said while incorporating measures such as better insulation and solar panels is now considered "best practice" in the construction industry, he said the public is still swayed by an "unfortunate financial view" that sustainability costs extra.
"A lot of professionals in the built environment know that sustainability is an important component and that there are more and more arguments suggesting that it should be part of building," he said.
"However, if the client – who technically is your boss – think that they are not gaining anything financially, then they can axe anything and leave the planner in an awkward situation.
Pryde said more education was needed to ensure clients understood the implications of their design choices.
"We can help people by providing a really good house that's climate change ready, but when the market wants what the market wants, that makes it really difficult for planners," she said.


Okay, I am embarrased to ask, but if we finish the top does that count or do we have to have it completely finished, ie, quilted & bound?
Hi Chelle, I would like to participate in the Official 2019 UFO Challenge. I'm not sure how many projects I will be able to work on as I have some unexpected quilting commitments at times, though I have finished 4 quilts since Christmas, many of them I can't share pictures of till a later date.
Oh for gosh sakes I WILL finish #4 Fall TT.


text:
The Music of Joni Mitchell
Hudson Valley Community College's Maureen Stapleton Theatre
When the dust settles, Joni Mitchell may stand as the most important and influential female recording artist of the late 20th century. Allmusic. Producer and bassist Scott Petito assembles a world class ensemble of the regions most well-respected musicians to interpret the timeless music of Joni Mitchell, perhaps best known for Both Sides Now and Big Yellow Taxi. Considered 1960s and 1970s folk royalty, the Canadian-born artist won her first of eight Grammys for Clouds (1969). In 21 albums (excluding compilations), Mitchell displays a limitless talent for wry and pointed lyrics, and largely self-invented musical chords, a kind of calligraphy of moods. Her voice is indescribable. Joining Petito on stage are Gail Ann Dorsey, Veronica Nunn, Leslie Ritter, Jay Collins, Danny Blume, Roberto Rodriguez, Travis Shook and special guest, Rachel Z.
Tickets will be available at the door on Friday, April 27.
Hudson Valley Community College's Maureen Stapleton Theatre (View)
80 Vandenburgh Avenue

redpajama_set_name: RedPajamaCommonCrawl


5/6 update below – worth a read.
Am I Mad as Hell, and Am I Not Gonna Take it Any More?
No, I'm slightly peeved, and completely resigned to taking it some more.
Over a neighbor's farm, April 25, 11:15 am.
Maybe the next question is, who cares? So what if there are dozens of contrails spreading overhead, rather wide and low and persistent and marring an otherwise perfectly clear blue sky? I care a little; but more than that, I'm just curious. If a giant silvery disc hovered over downtown Rockland, we could say, "Oh, that's just a bloated gasbag of an airplane with no wings, don't worry about it," but I venture to think we wouldn't be so dismissive of such an obvious elephant in the room.
Okay, back to the research. What I've learned breaks into three neat categories (and apologies if this reminds you of Donald Rumsfeld): What we know for sure, what we are pretty sure of, and what is otherwise speculation.
Now the military angle: I spoke with Jeff Northgreaves, airport manager at Knox County Regional Airport, and asked if anyone at the airport had noticed or mentioned all this activity on Friday morning. He said no, but after we talked for a bit he thought it could have been a military exercise – he had received notice of such an exercise with the 104th Fighter Wing out of the air force base at Westfield, Mass., along with members of the Civil Air Patrol. But, he ventured to say, these exercises happen at altitudes too low to generate contrails, and anyway, they held an exercise on April 29, not April 25. So, it wasn't them. I want to thank Jeff for being so accommodating and helpful with some subject matter that can get pretty far out there if we're not careful – so thanks!
Jeff also added, when I told him my blog was partly about food, that Steve Carell has just opened a cafe at the airport terminal. Now if that's the same Steve Carell of "The Daily Show" and "Despicable Me," I'll eat there anytime! I think it is the same Steve Carell – lucky us!
Chemtrail conspiracy theorists, suspicious of the U.S. government, are certain that the military is using this technique to seed the lower stratosphere with microscopic particles of aluminum and barium oxide emitted in jet aircraft exhaust. Some climate engineers point out that the Welsbach seeding might actually "work." This depends on what you mean by making something "work" in more than a narrow technical sense.
I'm attaching here the bulk of his email to me, which has some fascinating stuff in it, including what Welsbach materials are (essentially, lightweight metal oxides like aluminum, barium, and thorium oxides). For the record, I did show Dr. Fleming the photo of the sky over the Gig Store, but beyond conventional contrails he had no specific thoughts about what was happening up there.
I need to add that it's obvious the producers of the film invited Dr. Fleming because of his credentials, and edited him so tightly that his comments are not in context. He does not (and did not) subscribe to the show's premise, and it's clear his isolated remarks are positioned to bolster the film's bias.
Thanks to him for his considerable help.
It's been suggested I post radar images of the previous hour's flight activity because their contrails can linger. But what we saw at 11:15 was pretty much gone a half hour later – just vague white wisps.
Most of the effluvial spray we saw was to the south of us, and a little east and west of south. Radar shows almost no one there. Okay, I'm starting to get a bit peeved about all this.
Same place and time… again, except for the stuff on the horizon, all these are man-made.
What do I think? I don't think it matters, because I'm only slightly peeved and completely resigned to taking it some more, as I noted at the top of this post. But there are zillions of people who are really p*ssed, scientists who hate taking soil samples after a "chemtrail" only to discover hugely increased levels of aluminum and barium, mothers of autistic children who claim the aluminum is to blame for the affliction, farmers who find their crops in a "chemtrail" area stunted and unthriving, and so on through a long list of folks who look up at the sky and actually see the elephant in the room.
Fri. May 2 note: I find The Guardian to an excellent source for news, including articles on geoengineering. An Oct. 2011 blog post by John Vidal fingers the Bipartisan Policy Center (BPC), a DC-based think-tank of mixed "hawks," "neocons," and "neo-liberals," as leaders of the charge for direct intervention in geoengineering, which they like to call (*sigh*) "climate remediation." On this panel are big names in geoengineering like Canadian environmental scientist David Keith and atmospheric scientist Ken Caldeira, both of whom oversee Bill Gates' geoengineering research budget. The project has huge support from a web of oil, banking, and energy tycoons in the U.S.
Dig into it a bit, it gets pretty scary.
This email came in last night from Julius Hibbert, an ADS-B operator (Automatic Dependent Surveillance-Broadcast) in Bangor, and corrects me – in a forbearing way – on some of my assumptions, so I post here in its entirety. I've had to remove his hyperlinks because of problems saving this post, but you can cut and paste them in. Thanks, Julius!
Hi Ned! Saw your post on contrails over the gig. Interesting, but I think a few more facts may be helpful. Let me start by asking you this: you cite flightradar.24 as your source, but do you know where they get their data from? It comes from a combination of the FAA, and from myself (as well as hundreds of others,) who run ADS-B receiving stations. I operate one in Bangor, and feed ADS-B data to flightradar and other sites for flights that cover all of Maine. As an experienced operator, I can tell you that your assertion of "these are not commercial or civilian flights" is completely wrong. Certainly some are military. But flightradar24.com data is not complete. You will only see two categories of planes: those for which FAA provides tracking data, and those for which ADS-B data is available. FAA tracking data is not available for MANY private flights (think about John Travolta, for example,) due to operators requesting that their data be blocked. Most private jet owners fall into this category (Google FAA private flight tracking data for more info.) As for ADS-B, most planes do not have it yet, as the FAA has mandated that it is not required until Jan 1, 2020. Consequently, flightradar24.com and all other tracking flights only show a fraction of the true civilian traffic at any given time. You'd be amazed how how many civilian flights are up there constantly.
As to your statement that ""the layering and crosshatching of the contrails suggest an organized, coordinated exercise," reflects another common misconception about air travel. Airlines are not free to roam as they please, and, rather, follow strict "roads" in the sky defined by the FAA. Consequently, a dozen planes may follow the exact same path in the space of 60 minutes, and as the high altitude winds carry the contrail of the previous plane off the track, the next plane leaves a new contrail. You can easily see how "stripes" would form from normal commercial traffic. Check out the route maps at http://skyvector.com/ for example, and see that J573 on the Enroute H11 (one of many layers of routes) passes over the midcoast area.
To summarize, a little more fact finding would go a long way to dispel internet hokum. Thanks for your posts, and they were good pictures. The sky is an amazing place!


text:
import base64
import unittest
from flask import Flask
from flask_httpauth import HTTPBasicAuth, HTTPTokenAuth, MultiAuth

class HTTPAuthTestCase(unittest.TestCase):
    def setUp(self):
        app = Flask(__name__)
        app.config['SECRET_KEY'] = 'my secret'

        basic_auth = HTTPBasicAuth()
        token_auth = HTTPTokenAuth('MyToken')
        custom_token_auth = HTTPTokenAuth(header='X-Token')
        multi_auth = MultiAuth(basic_auth, token_auth, custom_token_auth)

        @basic_auth.verify_password
        def verify_password(username, password):
            if username == 'john' and password == 'hello':
                return 'john'

        @basic_auth.get_user_roles
        def get_basic_role(username):
            if username == 'john':
                return ['foo', 'bar']

        @token_auth.verify_token
        def verify_token(token):
            return token == 'this-is-the-token!'

        @token_auth.get_user_roles
        def get_token_role(auth):
            if auth['token'] == 'this-is-the-token!':
                return 'foo'
            return

        @token_auth.error_handler
        def error_handler():
            return 'error', 401, {'WWW-Authenticate': 'MyToken realm="Foo"'}

        @custom_token_auth.verify_token
        def verify_custom_token(token):
            return token == 'this-is-the-custom-token!'

        @custom_token_auth.get_user_roles
        def get_custom_token_role(auth):
            if auth['token'] == 'this-is-the-custom-token!':
                return 'foo'
            return

        @app.route('/')
        def index():
            return 'index'

        @app.route('/protected')
        @multi_auth.login_required
        def auth_route():
            return 'access granted:' + str(multi_auth.current_user())

        @app.route('/protected-with-role')
        @multi_auth.login_required(role='foo')
        def auth_role_route():
            return 'role access granted'

        self.app = app
        self.client = app.test_client()

    def test_multi_auth_prompt(self):
        response = self.client.get('/protected')
        self.assertEqual(response.status_code, 401)
        self.assertTrue('WWW-Authenticate' in response.headers)
        self.assertEqual(response.headers['WWW-Authenticate'],
                         'Basic realm="Authentication Required"')

    def test_multi_auth_login_valid_basic(self):
        creds = base64.b64encode(b'john:hello').decode('utf-8')
        response = self.client.get(
            '/protected', headers={'Authorization': 'Basic ' + creds})
        self.assertEqual(response.data.decode('utf-8'), 'access granted:john')

    def test_multi_auth_login_invalid_basic(self):
        creds = base64.b64encode(b'john:bye').decode('utf-8')
        response = self.client.get(
            '/protected', headers={'Authorization': 'Basic ' + creds})
        self.assertEqual(response.status_code, 401)
        self.assertTrue('WWW-Authenticate' in response.headers)
        self.assertEqual(response.headers['WWW-Authenticate'],
                         'Basic realm="Authentication Required"')

    def test_multi_auth_login_valid_token(self):
        response = self.client.get(
            '/protected', headers={'Authorization':
                                   'MyToken this-is-the-token!'})
        self.assertEqual(response.data.decode('utf-8'), 'access granted:None')

    def test_multi_auth_login_invalid_token(self):
        response = self.client.get(
            '/protected', headers={'Authorization':
                                   'MyToken this-is-not-the-token!'})
        self.assertEqual(response.status_code, 401)
        self.assertTrue('WWW-Authenticate' in response.headers)
        self.assertEqual(response.headers['WWW-Authenticate'],
                         'MyToken realm="Foo"')

    def test_multi_auth_login_valid_custom_token(self):
        response = self.client.get(
            '/protected', headers={'X-Token': 'this-is-the-custom-token!'})
        self.assertEqual(response.data.decode('utf-8'), 'access granted:None')

    def test_multi_auth_login_invalid_custom_token(self):
        response = self.client.get(
            '/protected', headers={'X-Token': 'this-is-not-the-token!'})
        self.assertEqual(response.status_code, 401)
        self.assertTrue('WWW-Authenticate' in response.headers)
        self.assertEqual(response.headers['WWW-Authenticate'],
                         'Bearer realm="Authentication Required"')

    def test_multi_auth_login_invalid_scheme(self):
        response = self.client.get(
            '/protected', headers={'Authorization': 'Foo this-is-the-token!'})
        self.assertEqual(response.status_code, 401)
        self.assertTrue('WWW-Authenticate' in response.headers)
        self.assertEqual(response.headers['WWW-Authenticate'],
                         'Basic realm="Authentication Required"')

    def test_multi_malformed_header(self):
        response = self.client.get(
            '/protected', headers={'Authorization': 'token-without-scheme'})
        self.assertEqual(response.status_code, 401)

    def test_multi_auth_login_valid_basic_role(self):
        creds = base64.b64encode(b'john:hello').decode('utf-8')
        response = self.client.get(
            '/protected-with-role', headers={'Authorization':
                                             'Basic ' + creds})
        self.assertEqual(response.data.decode('utf-8'), 'role access granted')

    def test_multi_auth_login_valid_token_role(self):
        response = self.client.get(
            '/protected-with-role', headers={'Authorization':
                                             'MyToken this-is-the-token!'})
        self.assertEqual(response.data.decode('utf-8'), 'role access granted')

    def test_multi_auth_login_valid_custom_token_role(self):
        response = self.client.get(
            '/protected-with-role', headers={'X-Token':
                                             'this-is-the-custom-token!'})
        self.assertEqual(response.data.decode('utf-8'), 'role access granted')

redpajama_set_name: RedPajamaGithub


text:
info@stockmarketpress.com
Spotlight Companies
SMP Blogs
SMP Seeking Alpha
Canna press
SMP HEADLINES
Tesla, Inc. (NASDAQ: TSLA) Doubles Down On Solar, Introducing Its Own In-House Solar Inverter And May Deploy 'Powerwall' Energy Storage…
Blink Charging Co. (NASDAQ: BLNK) Investment Conference Presentation Sees EV Electric Charging Station Market As Early In Its Growth Cycle;…
EV Electric Charging Stations Will Reach $39.2 Billion Globally By 2027; Solar Integrated Roofing Corp. (OTC PINK: SIRC) Joins Tesla,…
David Massey, CEO of Solar Integrated Roofing Corp. (OTC PINK: SIRC) Eyes Up List To QX Exchange And Becoming Fully…
Elon Musk, CEO of Tesla, Inc. (NASDAQ: TSLA), Says Solar Is A 'Killer Product," Almost Triples Solar Deployments Sequentially And…
Newest Trend In Solar Power And Green Agriculture — Agrivoltaic Systems — Could Reduce Carbon Emissions And Create More Rural…
Banks And Hedge Funds Worldwide Seeking Clean Energy Foothold For Solar And Green Funding While Cutting Fossil Fuel Projects; Solar…
Solar-Seeking Residential Homeowners Find One-Stop-Shopping In Solar Integrat-ed Roofing Corp. (OTC PINK: SIRC) With Solar Roofs Installation, Solar Systems, Solar…
Medical Cannabis Is Seeing A Surge In Interest From Key Players
Home / NASDAQ:CRON / Medical Cannabis Is Seeing A Surge In Interest From Key Players
By Shannon Roxborough
In NASDAQ:CRON, NASDAQ:NEPT, NASDAQ:TLRY, NYSE: ACB, NYSE:STZ, OTC: DIRV, OTC: MMNFF, OTCQB:CWBHF, OTCQB:MMNFF, OTCQB:MSPC, QTCQB:LDSR
Medical Cannabis Is Seeing A Surge In Interest From Key Players2019-05-102020-01-24https://www.stockmarketpress.com/wp-content/uploads/2020/01/stock-new-01.pngStock Market Presshttps://www.stockmarketpress.com/wp-content/uploads/2019/01/pic1.png200px200px
New York, NY May 10, 2019 – Stock Market Press is a leading financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network sees the medical cannabis market expanding across the globe.
More and more countries are allowing research using medical cannabis, both CBD and THC varieties. It has been a long time coming. Passage of the 2018 Farm Bill in the USA and the legalization across Canada are just two examples of restrictions being eased or removed entirely.
Recent research and analysis sees the legal marijuana market topping $145B by 2025. The world of medicine is finally breaking free from the incredible stranglehold that big pharma has had. We are seeing adoption of marijuana in multiple medical categories, from cancers to mental health issues, from chronic pain to seizures. Not only is the demand so great, but the results are so impressive that the FDA recently approved the first CBD containing drug.
All this interest in legal (recreational) and medical cannabis has companies like Tilray Inc. (NASDAQ:TLRY) investing more money into infrastructure for production and manufacturing.
Tilray® Announces Investment to Expand Canadian Production and Manufacturing Footprint to Increase Supply of Medical and Adult-Use Cannabis
Tilray Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced an investment of US$32.6M to increase the company's Canadian cannabis production and manufacturing footprint by 203,000 square feet across three facilities. This investment will expand Tilray's total production and manufacturing footprint from 1.1 million to 1.3 million square feet worldwide.
That's an almost 20% increase across three facilities. Strong indication that the market is set to explode later this year. Further confirmation of this growth comes out of Europe with Aurora Cannabis Inc.'s (NYSE:ACB) recent supply announcement.
Aurora Cannabis Inc Aurora Cannabis Extends Exclusive Supply Relationship with Luxembourg
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (NYSE:ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company, through its wholly owned subsidiary Aurora Deutschland, has been selected by the Luxembourg Health Ministry as the exclusive supplier in a public bid to supply a second delivery of medical cannabis to Luxembourg.
Under the terms of the bid, the medical cannabis produced will be sold to Luxembourg's Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from the Luxembourg government. While the initial bid quantities are small, the award confirms Aurora's position as a trusted and preferred supplier to international jurisdictions and reflects the Company's ability to work with local governments and regulators in complex, restricted markets.
Medical and recreational cannabis markets continue to attract huge interest as can be seen from just the two examples listed above. The FDA is expected to continue reviewing CBD based drugs which will further push the US Congress to ease restrictions on marijuana. This will be a goldmine to investors.
Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Stock Market Press
110 Wall St.
info@wordpress-61181-1001021.cloudwaysapps.com
https://twitter.com/PressStock
Safe Harbor Statement:
Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://www.stockmarketpress.com/disclaimer/
SOURCE: Stock Market Press
Shannon Roxborough
Shannon Roxborough is SMP's senior contributor writer. A financial journalist for more than 20 years, he has covered U.S. and global markets across all sectors. A former correspondent with Money magazine and columnist with Small Cap Investor, his writings have appeared in The Wall Street Journal and numerous other financial publications.
Company Name: American Premium Water
Email: info@website.com
Please read Disclaimer for FULL Compensation Disclosures and other disclaimers.
Copyright 2016 - 2020 Stock Market Press. All rights reserved


text:
Склад ради
Рада складалася з 18 депутатів та голови.

Керівний склад ради

Примітка: таблиця складена за даними джерела

Джерела
 Картка ради на сайті Верховної Ради України
 Миколай-Пільська селищна рада

Примітки

Адміністративний устрій Запорізького району

redpajama_set_name: RedPajamaWikipedia


text:
auth/auth_ldap
==============

The `auth/auth_ldap` plugin uses an LDAP bind to authenticate a user. Currently
only one server and multiple DNs can be configured. If any of the DN binds succeed,
the user is authenticated.

Configuration
-------------

Configuration is stored in `config/auth_ldap.ini` and uses the INI
style formatting.

Only the `LOGIN` authentication method is supported assuming that passwords in the
LDAP database are not stored in cleartext (which would allow for CRAM-MD5). Note
that this means passwords will be sent in the clear to the LDAP server unless
an `ldaps://` conection is used.

Current configuration options in `[core]` are:

    server - the url of the LDAP server (ldap:// or ldaps://)
    timeout - time in miliseconds to wait for the server resonse before giving up
    rejectUnauthorized - boolean (true or false) as to whether to reject connections
        not verified against a CA. Meaning, a "false" allows non-verified.

Example:

    [core]
    server=ldaps://ldap.opoet.com
    timeout=5000
    rejectUnauthorized=false

The `[dns]` section (that is plural DN and not domain name system), is a list of DNs to use
to bind. The `%u` in the strings is substituted with the user name used in the SMTP
authentication. Note that the keys have no meaning and the DNs are tried in series until
the first successful bind. The LDAP RFC does not allow for parallel binds on a connection,
so it is suggested that the most commonly used DN be placed earlier in the list.

Example:

    [dns]
    dn1=uid=%u,ou=Users,dc=opoet,dc=com
    dn2=uid=%u,ou=people,dc=opoet,dc=com


About The Way Lies North: During the American Revolution, Charlotte and her Loyalist family are forced to flee from their home.
"We've had word from my brothers," Charlotte said. "They're all in the same battalion. Isaac writes—"
"Stop! Don't tell me about it. I hate this war." Nick was staring across the ravine to the hills on the far side. His jaw was clenched. He'd been moody like this for months. She wanted to reach out her hand to brush back the lock of blond hair that fell across his brow, but a sense of hard separateness prevented her.
"We have to fight for what we believe in," she said.
"Because duty matters. I would fight if I were a man."
A hopeless feeling came over her because Nick was a Whig and she was a Tory. He loved her, and she loved him, but that seemed to matter less and less.
It's the American Revolution. There are two sides. This splits Charlotte and her sweetheart apart. Charlotte and her family flee for freedom. Along the way, Charlotte makes new friends and learns customs of other people.
I haven't read a book that follows a war in a while. Mostly because the only ones I could find were for younger people or older people. I was very happy to have found it and very pleased with it overall. It had a good intense storyline that kept me reading which is always good.
I'd strongly recommend this book to anyone who is in the same situation I was in.
Reviewed by KB, age 14, on 25 January 2009.


text:
1. Create a new blank project in ArcGIS AppStudio
2. Launch QtCreator (AppStudio)
3. Replace the contents of your main.qml(or empty.qml) file with the contents of MyApp.qml
4. Save, and run the App through AppStudio

## Resources
* [Polygon Class](https://developers.arcgis.com/qt/qml/api-reference/class_polygon.html)
* [MultiPath Class](https://developers.arcgis.com/qt/qml/api-reference/class_multi_path.html)
* [Feature Layer Class](https://developers.arcgis.com/qt/qml/api-reference/class_feature_layer.html)

### Author
* Alexander Nohe


Build immersive experiences for web, tablet, and mobile with the Now UI kit.
NOW's clean, simple design makes it a perfect fit for today's flat aesthetic.
Components designed on a high-quality, 12-column grid.
Built with free, high-quality web fonts for easy editing.
Get the Now UI kit today.


Over the past year I've been involved in helping to set up and facilitate 'Ebb & Flow', a collaboration between five Ipswich secondary schools, five digital writers, USC, and artsroute, an innovative arts-in-schools project based in Ipswich.
'Ebb & Flow' took shape slowly, starting with a boattrip down the River Orwell with all the kids last autumn, to collect digital assets - photos, videos, sounds, etc - for the project. The project then continued with digital story workshops run by digital writers Tim Wright, Chris Meade, and JR Carpenter. I helped run two further workshop days to begin to pull the project together, before Andy Campbell of One to One Development Trust stepped in to design and create the fabulous website for the project.
Tony Newman of artsroute and I have learned a lot from creating 'Ebb & Flow' - in fact we might have learned more about how not to run a schools digital stories project then anything else. However, we are both incredibly pleased with the outcome, with the wonderful stories and images you'll find on 'Ebb & Flow', and for the way that students, teachers, and writers worked together to think about new ways of telling stories.
For those of us who are interested in such things, Andy has also created a version of the project that is viewable on smartphones - just go to the project url using your phone's browser: http://www.ebbflow.co.uk/ .


text:
ADA Standards of Medical Care
Special Article Collections
OtherReviews/Commentaries/Position Statements
Zachary T. Bloomgarden
DOI: 10.2337/diacare.26.1.230 Published 1 January 2003
Find this author on ADS search
Find this author on Agricola
ACE, angiotensin-converting enzyme
ARB, angiotensin receptor blocker
BARI, Bypass Angioplasty Revascularization Investigation
CABG, coronary artery bypass graft
CHF, congestive heart failure
CML, carboxymethyllysine
CVD, cardiovascular disease
DCCT, Diabetes Control and Complications Trial
DECODE, Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe
IFG, impaired fasting glucose
IGT, impaired glucose tolerance
IMA, internal mammary artery
LVH, left ventricular hypertrophy
MG, methylglyoxal
NF, nuclear factor
SU sulfonylurea
UKPDS, U.K. Prospective Diabetes Study
This is the fourth in a series of articles covering the 2002 American Diabetes Association Annual Meeting, San Francisco, CA, 14–18 June 2002.
Mortality and morbidity in diabetes
Peter Savage (Ellicott City, MD) discussed secular trends in cardiovascular disease (CVD) among patients with diabetes. Two-thirds to three-quarters of patients with diabetes will eventually die of CVD. Diabetes is becoming more important as a cause of CVD in the population because of its increasing prevalence, due to the high incidence in minority populations and the increasing obesity of the population. The "key question," Savage stated, is whether persons with diabetes are different from those without diabetes in not enjoying the same decline in CVD that has been seen in the overall population over the past 50 years, presumably reflecting a variety of advances in the treatment of risk factors. In a study of time trends in mortality in U.S. adults between surveys in 1971–1975 and in 1982–1984, diabetic men had a decline of 13% in age-adjusted CVD mortality, while that for nondiabetic men was 36%, and diabetic women had an increase of 23%, while women without diabetes had a decline in CVD mortality of 27% (1). Although microvascular disease is relatively specific for diabetes, macrovascular disease appears as an acceleration of the illness seen in persons without diabetes. High LDL is a risk factor in those with and without diabetes, but persons with diabetes tend to have low HDL, high triglyceride, and abnormal LDL particle size. They have the hypertension of the insulin resistance syndrome, which becomes exacerbated with renal disease (and diabetic patients with renal disease have extraordinarily high rates of CVD). Diabetes is associated with coagulation abnormalities and inflammation, as well as hyperglycemia, glycation, and secondary effects on CVD risk factors. Insulin resistance and hyperinsulinemia are additional factors in persons with diabetes.
Savage pointed out that persons with diabetes and CVD have poorer overall prognosis, with poorer short-term survival, increased risk of recurrent disease, poorer response to surgery, and increased risk of congestive heart failure (CHF). There are particular problems in minority populations, whose CVD rates appear to be increasing, with diabetes a more important risk factor in these groups. Data are, however, somewhat limited and longitudinal follow-up is particularly difficult to obtain, particularly in view of changing diagnosis and treatment of diabetes and risk factors and given the new classification criteria. In the Framingham Heart Study, assessment of the relative CVD risk of those with diabetes compared with those without in 1956, 1966, 1972, and 1979 suggests little relative change at approximately twice the level seen in nondiabetic individuals. Other studies have shown, however, that death rates from CVD in the U.S. from 1985 to 1999 have declined in nondiabetic men and women in most ethnic groups, though to varying degrees, while there may be an increase in CVD in American Indian populations, perhaps in association with their high prevalence of diabetes.
The effects of treatment of patients with diabetes with statins are similar to those for nondiabetic groups. Blood pressure lowering also appears to convey similar relative benefit to patients with and without diabetes. Thus, CVD risk factor treatment is at least as effective as it is in persons without diabetes, although the greater absolute risk of diabetic subjects gives them greater absolute benefit from the interventions. One difficulty may be that patients with diabetes require such a great deal of preventive treatment; subsequently, their rates of compliance with recommended treatment may be lower than desirable.
The Cardiovascular Health Study showed that rates of glucose, blood pressure, and lipid control, and of aspirin administration for older persons with diabetes, are less likely to be at goal than for those without diabetes (recognizing that goals are stricter for persons with diabetes) (2). Savage concluded that there is only limited evidence that patients with diabetes are benefiting less from the decline in CVD, and that there are some unique aspects of CVD in persons with diabetes that require particular attention. He stated that the "benefit of controlling hyperglycemia on CVD risk remains to be proven," although he believed it was an appropriate goal. He pointed out the importance of aggressive control of known risk factors, the need for heightened provider awareness and effort, and the need for improved health care system support.
Steven Haffner (San Antonio, TX) discussed the primary prevention of CVD in patients with type 2 diabetes. (For a summary of this presentation, see http://diabeteshighlights.org/summary/summary.asp?sid=1&stid=15&ld= 2002-06-17.) Levels of prevention can be classified as primary prevention of diabetes itself, secondary prevention of complications in diabetic subjects free of disease, and tertiary prevention of further complications in those persons with diabetes who already have evidence of CVD. Haffner pointed out that there is high out-of-hospital mortality before first myocardial infarction in men with diabetes (3) and increased CVD prior to the onset of type 2 diabetes (4), suggesting that the truly appropriate approach should be diabetes prevention rather than frequent screening and treatment of those persons who have evidence of CVD. Prevention studies include the Da Qing Study (showing 31–46% risk reduction), the Finnish Prevention Study (showing 58% risk reduction), the Diabetes Prevention Program, and STOP-NIDDM (showing 25% reduction); thus, a variety of approaches may be useful. In addition, there is evidence that pravastatin, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blocker (ARB) treatment may reduce rates of development of diabetes by 25–30%. Two major clinical trials are in progress, the Diabetes REduction Approaches with ramipril and rosiglitazone Medications (DREAM) Study and the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study, to further address approaches to prevention of diabetes and CVD complications.
Among persons with diabetes, risk factors in the Multiple Risk Factor Intervention Trial (MRFIT) show similar effect, but at higher rates than in persons with diabetes (5). In the U.K. Prospective Diabetes Study (UKPDS), glycemic and blood pressure treatment decreased in microvascular and macrovascular disease. Also, metformin may have led to greater benefit than sulfonylurea (SU) and insulin, but this is unclear as those patients treated with metformin plus SU did less well than those treated with SU alone. Epidemiologic analysis of the UKPDS shows correlations of both hypertension and hyperglycemia with microvascular and macrovascular disease, with the latter group of complications, which are more common, being less affected by glycemia than by hypertension. The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) and other studies show that postglucose load hyperglycemia may be particularly disadvantageous, so that the HbA1c alone may be insufficient for fully appreciating the adverse effect of glycemia. Haffner also reviewed data showing that hyperinsulinemia in nondiabetic persons is associated with adverse CVD risk.
Epidemiologic analysis suggests optimal systolic blood pressure levels to be <120 mmHg. Blood pressure treatment is effective, with interesting new data that ARBs may be better than β-blockers in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) study (6). Multivariate analysis of baseline characteristics of patients in the UKPDS shows dyslipidemia to be the major predictor of CVD risk (7). Haffner reviewed the Heart Protection Study, which showed benefit of statins in persons with diabetes, with both LDL cholesterol levels >100 mg/dl and lower LDL cholesterol levels (8). Fibrates have shown benefit in patients with diabetes in the Helsinki Heart Study, the Diabetes Atherosclerosis Intervention Study (DIAS), and the Veterans Affairs HDL Cholesterol Intervention Trial (VA-HIT), with coming trials addressing potential benefits of combination treatment with fibrates plus statins. Nicotinic acid, particularly in moderate doses, may offer another approach for lipid treatment for persons with diabetes. The Adult Treatment Panel (ATP) III guidelines suggest that the primary target of therapy to be LDL cholesterol, and considers diabetes to be a CVD risk equivalent, so that the goal for persons with diabetes is LDL <100. After the LDL goal is met, if triglyceride levels exceed 200 mg/dl, lowering the non-HDL cholesterol below 130 mg/dl becomes a secondary target (9). These guidelines also suggest that persons with the metabolic syndrome are at high risk, resulting in a population of ∼21 million persons in the U.S. requiring risk factor treatment. This figure is in addition to the 13 million persons with diabetes in the U.S., 90% of whom also have features of insulin resistance. There are interesting studies of the effects of thiazolidinediones on surrogate markers for CVD, and ongoing studies of outcome with these agents will be important.
As goals, Haffner suggested having an HbA1c <7%, or, perhaps, referring to the AACE recommendations, 6.5%; having blood pressure <130/80 mmHg, with ACE inhibitors and ARBs the preferred agents; and having LDL cholesterol <100, HDL cholesterol >45, and non-HDL cholesterol <130 mg/dl. Special interventions to be considered may include attention to postprandial glycemia and use of antioxidants.
Robert Frye (Rochester, MN) discussed secondary prevention of CVD in patients with diabetes, addressing outcomes of coronary revascularization in type 2 diabetes and features of secondary prevention. The Bypass Angioplasty Revascularization Investigation (BARI) compared angioplasty with coronary artery bypass graft (CABG) in patients with multivessel coronary disease who had angina and were eligible for either approach at a time prior to the availability of stents (10). The CABG approach used internal mammary artery (IMA) grafting in 82% of persons treated, with a mean of 3.1 arteries bypassed. For those without diabetes, at 10 years, CABG and PTCA led to virtually identical 78.2 and 76.8% survival in 734 and 742 patients. For those with diabetes, however, the 10-year mortality levels were 57.1 and 44.1%, respectively, in 180 and 173 patients, with all of the excess mortality being due to cardiac disease. Those who did not have an IMA graft, interestingly, did not have the same degree of benefit as those for whom this procedure was performed. Both patients receiving oral agents and those receiving insulin had similar gradient of CABG being better than angioplasty, although the insulin-treated group showed worse outcome. The BARI 2D study has been designed to reduce cardiac mortality in patients with type 2 diabetes through the comparison of aggressive medical therapy with and without immediate revascularization, as there is no proof that the latter improves mortality, and the comparison of insulin sensitizer and secretagogue treatment to reach a goal of an HbA1c <7%.
Helen Vlassara (New York, NY) gave the Edwin Bierman Lecture on genes versus environment in the complications of diabetes. The steep rise in incidence of diabetes with aging (11) and its increase in frequency in the population suggest the importance of assessing the underlying genetic predisposition to diabetes and its complications. Hyperglycemia, via glycation and increase in activity of the protein kinase C pathway, appears to cause oxidative stress. Both proteins and phospholipids are modified by glycation with reducing sugars, and subsequent oxidation may contribute to diabetic complications. A large number of glycated chemical structures exist, with 4-hydroxyhexenal, a precursor to one of the major metabolites of lipid hydroperoxide degradation, and related forms appearing to be important in the reactions. The advanced glycation end products (AGEs) are now seen as rapidly developing inflammatory molecules affecting a variety of target organs. The AGE receptors, AGE-R1, R2, and R3, receptor for AGE (RAGE), and the scavenger receptor, exist in monocyte/macrophages, T-cells, endothelial cells, renal mesangial and tubular cells, fibroblasts, smooth muscle cells, and neuronal and glial cells. AGEs have important interactions with lysozyme, lactoferin, defensins, and galectins, resulting in endocytosis, degradation, and signaling increasing levels of reactive oxygen species, inflammation, and vascular permeability, and causing a procoagulant state. It is noteworthy that there are AGE receptor polymorphisms, perhaps explaining variations in susceptibility to complications. AGE-R1 overexpression suppresses nulcear factor (NF)-κB in endothelial cells, so that there may be beneficial and as well as adverse effects of AGEs.
Vlassara noted that AGEs are not only derived from high blood glucose, but also have exogenous sources, absorbed from diet (12) and from cigarette smoke, which leads to glycation of lipids and proteins. Tissue carbonyl-compounds, such as derivatives of carboxymethyllysine (CML) and methylglyoxal (MG), correlate with their dietary loads. In particular, LDL isolated from patients with diabetes after high AGE meals are associated with adverse cellular effects in vitro. Low dietary AGE intake may be shown to decrease type 1 diabetes development in animal models, with a decrease in T-cell numbers and changes in lymphokine levels, suggesting an immune-modifying effect. In type 2 diabetes models, these diets reduce body weight and serum insulin levels and increase HDL cholesterol and adiponectin, with improvement in pancreatic islet morphology. In models of atherosclerosis, the low-AGE diet protect against atherosclerosis despite hyperglycemia and dyslipidemia. These diets also protect against diabetic nephropathy and appear to promote wound healing.
Persons with diabetes placed on diets of low-AGE content show influences on CML, MG, and AGE-LDL modification, with lower levels of C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and vascular cell adhesion molecule (VCAM)-1, suggesting that this approach may lead to clinical benefit. Vlassara suggested that diabetes alone might be less important than dietary AGE effects on complications, and that changing the environment in which persons with diabetes live may convey particular benefit. In a study from her laboratory, Cai et al. (706-P) administered diets differing fivefold in AGE content for 6 weeks to 10 persons with diabetes whose fasting glucose averaged 115 mg/dl with normal lipid levels (abstract numbers refer to ADA Scientific Sessions, Diabetes, Vol. 51, Suppl. 2). While patients followed the high AGE-diet, LDL had 2.1-fold higher CML levels and showed a 1.5-fold greater NF-κB stimulatory activity on human endothelial cells than LDL isolated from patients following the low-AGE diet. These data suggest the potential of dietary AGE to exacerbate vascular toxicity of diabetic LDL. Peppa et al. (69-OR) from this group studied the effect of dietary AGEs on wound healing in diabetic db/db (+/+) mice, showing full healing of a full-thickness 1-cm wound in 63% of mice on a low-AGE diet, but in only 38% on a diet with AGE levels five times higher. Glucose levels, food intake, and body weight were similar, but serum AGE levels were 52% higher and skin from mice on the high-AGE diet had two to three times greater levels of CML derivatives.
Wilson Tang (Cleveland, OH) addressed connections between diabetes and CHF and discussed the effects of insulin resistance in patients with heart failure. More than two-thirds of patients with diabetes will develop CVD. Patients with diabetes have similar CVD risk to those without diabetes with history of myocardial infarction. In 1972, autopsy studies showed left ventricular hypertrophy (LVH) and other histopathologic characteristics, suggestive of a specific entity of diabetic cardiomyopathy (13). Heart failure is a clinical syndrome, whereas the term "cardiomyopathy" refers to a structural abnormality. Insulin resistance has recently been recognized as an important characteristic of patients with CHF, with all the features of insulin resistance worsening CVD and contributing to CHF. Diabetes may not only produce vascular damage, but it may also impair glucose entry into cells, thereby causing myocardial injury. Cardiomyopathy may present with systolic or diastolic dysfunction, as well as with neurohumoral manifestations.
Tang suggested that it is necessary to identify cardiac dysfunction even without heart failure and that screening to identify LVH and LV dysfunction as potential targets for therapy should be practiced. In patients with diabetes, the Framingham Study showed increased risk of developing CHF (two- to threefold in men and three- to fivefold in women). Recent Kaiser Permanente registry analysis shows that diabetes is associated with increased prevalence and annual incidence of CHF (14). Female sex, age, ischemic heart disease, oral agent and insulin use, serum creatinine, and duration of diabetes are all predictors. Patients with lower HbA1c and those whose HbA1c fell during follow-up had higher incidence of CHF, though a biological explanation of this is uncertain.
Patients with diabetes and ischemic cardiomyopathy fare worse than those without diabetes, as shown from a recent analysis (15). There is no evidence that patients with diabetes have larger infarctions, a greater extent of coronary narrowing, or a greater degree of abnormal remodeling. The finding that glycemic control in the postmyocardial infarction period improves outcome suggests a potential adverse effect of glycemia (16). Patients with diabetes may also have blunting of the compensatory hyperkinesis of noninfarcted tissue and may have adverse effects of autonomic neuropathy.
An important question is why some patients have improvement in cardiac remodeling, while others fail to show such an improvement. In a comparison of carvedilol-treated patients who did and did not show benefit of treatment, there is evidence that those who respond have a greater prevalence of the insulin resistance syndrome. Early identification of CHF in persons with diabetes may be particularly important in leading to early initiation of treatment. Tang noted that metformin may be well tolerated as an insulin sensitizer among persons with CHF, although there is potential for toxicity with hepatic and renal dysfunction.
Richard B. Devreux (New York, NY) reviewed data from the Strong Heart Study of a Native American population with extremely high diabetes prevalence. Echocardiographic measurement of wall thicknesses and chamber diameter allows good estimation of LV mass. The risk of a variety of adverse end points is increased 2- to 10-fold in persons with LVH, with increased mortality. Diabetes, adjusted for a variety of other potential risk factors, is associated with increased frequency of LVH by a number of measures, independent of age, blood pressure, antihypertensive treatment, and obesity. Persons with diabetes and LVH have 1.5- to 2-fold increases in rates of morbid events, suggesting a role of echocardiography in determining which patients should be placed on multiple medication regimens.
Dividing the Strong Heart Study into patients with and without diabetes and with and without hypertension, the frequency of LVH is ∼10% with neither, 20% with diabetes alone, 25% with hypertension alone, and nearly 40% among individuals with both risk factors. Similar data have been shown in other population groups. Persons with diabetes show decreased ventricular systolic function, again with additive effects of diabetes and hypertension. Ventricular contractility, again, is decreased in diabetes, in persons with hypertension, and, to a greater extent, in those with both abnormalities.
The LIFE trial with losartan showed decreased myocardial contractility among persons with diabetes and moderately severe hypertension, which was associated with increased mortality rates. Higher HbA1c levels were not associated with worse contractility, but measures of renal dysfunction showed strong correlation with worsening of these parameters. Abnormalities of diastolic ventricular relaxation are seen to a similar extent in persons with either diabetes or hypertension, with additive effects of the two factors. Abnormal LV relaxation was significantly more prevalent in persons with higher HbA1c, suggesting an effect of prevailing levels of glycemia.
Carotid wall thickness is influenced by both hypertension and atherosclerosis. Diabetes leads to greater and more diffuse carotid disease. Sixty percent of persons with diabetes have evidence of carotid atherosclerosis with presence of plaque. Arterial stiffness also increases with both diabetes and hypertension, the latter because of greater distending pressure of the arteries, which are stretched to their maximal size, whereas in diabetes the arteries, while not stretched, are almost as stiff.
Devreux ended with a discussion of the association between hyperinsulinemia and abnormal cardiac function. Fasting insulin shows significant association with a variety of measures of LVH as well as with increased cardiac output (17). Many of these associations are not significant on multivariate analysis, however, suggesting effects of age, BMI, and blood pressure, rather than primary effects of hyperinsulinemia. After adjustment for these factors, fasting insulin levels are related to greater LV size and cardiac output in men and to LV wall thickness in women.
This analysis suggests that an echocardiogram should be done in patients with type 1 and type 2 diabetes if signs or symptoms of CVD are present, or if one is considering intensive blood pressure treatment. Devreux noted that the echocardiographic abnormalities are highly prevalent and are seen within several years after the diagnosis of type 2 diabetes. "It would be in many clinical settings a luxury to routinely do echocardiograms on all diabetics," he stated, but "in the Strong 30% had LVH and about 20% had evidence of subnormal myocardial function […]. [T]hese are not rare abnormalities[…]. We are about to initiate a trial [of] the hypothesis that even more aggressive lowering of blood pressure and LDL will have beneficial effects in type 2 diabetes using echocardiographic and carotid artery measures of preclinical disease as our bioassay."
Postprandial hyperglycemia
Jaime Davidson (Dallas, TX) debated John Buse (Chapel Hill, NC), taking the position that postprandial glucose should be measured and monitored. Both tried to define goals and approaches to the treatment of this parameter. Davidson stated, "We need to have data, and we need to have judgment," pointing out that the ADA currently does not set goals for postprandial glucose levels, defined as the glucose level 2 h after the start of the meal. He referred to the ADA "postprandial glucose consensus" position statement, which points out that in normal individuals, glucose levels are maximal around 1 h after the beginning of a meal and rarely exceed 140 mg/dl, but that there is no definite evidence as to whether this should be a goal of therapy. According to the statement, these levels should be monitored with gestational diabetes, with suspected postprandial hyper- or hypoglycemia, and in patients receiving agents specifically directed at glucose during this period. Postprandial hyperglycemia is one of the earliest abnormalities in diabetes, so that monitoring this is necessary for full assessment of early diabetes. Davidson also noted that the postprandial glucose plays a major role in the determination of HbA1c levels, and that some studies suggest stronger correlation of HbA1c with post- than with preprandial glucose (18).
Has managing postprandial glucose been shown to improve HbA1c levels? In a comparison of 135 persons treated with glyburide for whom addition of insulin lispro was compared with treatment directed at the fasting glucose, either metformin or NPH insulin, the postprandial treatment approach with insulin lispro had the greatest effect in lowering HbA1c, although NPH insulin lowered fasting glucose most effectively (19). Similarly, in another study of persons with diabetes failing to respond to SU treatment, addition of insulin lispro lowered 2-h postprandial glucose from 335 to 254 mg/dl, with HbA1c decreasing from 9.0 to 7.1%. In a study of 66 women with gestational diabetes who required insulin therapy, preprandial monitoring with a glucose goal of 60–105 mg/dl (<90 fasting) vs. 1-h postprandial monitoring with a goal of <140 mg/dl resulted in improved HbA1c and outcome, with a marked reduction in neonatal hypoglycemia and Caesarean section in the latter group (20).
The DECODE Study showed that high 2-h glucose is associated with CVD mortality independent of fasting glucose (21). Similar findings were reported from Pacific and Indian Ocean populations, with isolated 2-h hyperglycemia associated with doubled mortality (22). Furthermore, analyses of various indicators of adverse CVD risk show that imparied glucose tolerance (IGT) but not impaired fasting glucose (IFG) is a CVD risk factor (23). In the Diabetes Intervention Study, among 1,139 persons with diabetes followed for 11 years, myocardial infarction and mortality increased more with postprandial than with fasting hyperglycemia (24). In the Honolulu Heart Study, the 1-h postchallenge glucose was associated with increased CVD (25). Finally, the Risk Factors in IGT for Atherosclerosis and Diabetes (RIAD) Study showed that 2-h postchallenge glucose was associated with increased carotid intima-media thickness, with fasting glucose not contributing in multivariate analysis (26).
"A glucose is a glucose," Davidson pointed out, implying that if postchallenge hyperglycemia is associated with increased risk, it should be treated. He stated that "a reasonable goal" is for the 2-h glucose to be <140 mg/dl, based on the levels in persons without diabetes, and asked, "If postprandial is bad in IGT, why is it not bad in patients with diabetes?" We desire to attain good glycemic control, he stated, and "unless we target all the glucoses that we need to target, we are not going to get there." Rather than criticizing this as being unsafe, he implied that studies such as the Diabetes Control and Complications Trial (DCCT) and Kumamoto, in which patients were tested at these times, may have had additional benefits such as reduced frequency of hypoglycemia. Subsequent to these studies, the development of rapidly acting insulin analogs and secretagogues targeting postprandial glycemia has further allowed us to improve HbA1c. "If you don't believe in tight control," Davidson commented, "then your patients are not going to believe in tight control." He asked whether "pressure from payers and other interested parties prevents us from doing what we need to do," and asked those treating patients with diabetes not to "give in" to these pressures.
Buse responded to Davidson's "eloquent and impassioned argument," stating that he had previously been a "therapeutic zealot," but was influenced by criticisms that before we "make leaps of faith that sometimes can be quite expensive," we must follow the results of clinical trials. "Clearly, measuring postchallenge glucose in screening for impaired glucose tolerance and for diabetes is extremely important," he stated, but "those are not truly postprandial glucose data," which "could be quite different." We "need to separate in our minds the well-defined benefits of agents which specifically manage postprandial glucose [from] the need for monitoring." He further criticized the "intensive marketing effort on the part of […] numerous pharmaceutical companies to further justify the need for their agents which specifically deal with postprandial glucose as well as device manufacturers which make their profit by the strip."
He stated that he agreed that the DCCT, Kumamoto, and UKPDS studies were, indeed, important, but argued that one cannot find any data in these studies that support the use of postprandial glucose testing. Although lowering of HbA1c is important, and "it is possible that treatment aimed at lowering postprandial glucose would lower HbA1c and therefore lower the risk of complications," such an approach has not been demonstrated to be effective. Reviewing the gestational diabetes study, he pointed out that when comparing a preprandial glucose target up to 105 mg/dl versus a postprandial glucose target up to 140, "the real driver of the difference in outcomes was that the preprandial target was just inadequate" as this group had a mean HbA1c of 7.5%. Further, when we aim for an HbA <7%, "it is clear that preprandial monitoring is necessary to discover unrecognized and unsuspected hypoglycemia as a first step to avoiding severe hypoglycemia." The fact that a 2-h blood glucose after oral glucose administration is associated with greater cardiovascular risk than the fasting glucose, he stated, need not mean that we need to monitor postprandial glucose, but, rather, indicates that one should use more sensitive markers for the insulin resistance syndrome. The 2-h glucose also is an indicator of abnormal insulin secretory dynamics, Buse noted, and in the Hoorn study report presented at the meeting, the 2-h glucose effect was not significant after correction for lipid and blood pressure, further suggesting that this is not "a primary treatment target." (See Dekker et al. [258-OR].)
As far as glycemic therapy, Buse stated, there is no good evidence that agents targeting postprandial glucose are more effective than those targeting preprandial glucose, and in any event, monitoring postprandial glucose need not be routinely performed in patients receiving such treatment. Finally, asking what is the appropriate target of postprandial glucose, he stated, "it's very hard to come up with a guideline that will work for everyone." Retinopathy increases at 2-h postchallenge glucose levels "that are really quite high," he commented. He referred to a study of glycemic patterns in nondiabetic persons given standard meals with 12.5, 25, and 50% of total daily calories. Peak plasma glucose varied as a function of meal size, reaching 159 mg/dl after the medium and 178 mg/dl after the large meal (although an audience questioner noted that these were peak and not 2-h postprandial glucose levels) (27). He agreed that one could use postprandial glucose measurement for certain patients, but suggested that this would only be relevant for those who had reached preprandial targets without achieving HbA1c targets or for those who had evidence of postprandial hypoglycemia. His target for postprandial glucose was 180 mg/dl for such circumstances, and he stated that "we need additional clinical trials to routinely advocate for the use of postprandial glucose monitoring in the management of type 2 diabetes." Furthermore, he stated, "Almost certainly having people perform extra glucose monitoring will prevent them from doing other things," considering the importance of not only glycemic treatment but also of lipid treatment, blood pressure treatment, etc. He mentioned that it has been considerably more of a challenge to achieve the postprandial goal of the ACCORD study of a 2-h glucose level <140 mg/dl than the other glycemic goals of HbA1c <6% and fasting glucose <105 mg/dl. A questioner noted that alternate site testing may lead to lower postprandial glucose levels than simultaneously measured fingertip or venous blood glucose, and Buse agreed that this would make optimizing postprandial glucose even more difficult.
At a symposium on the association of postprandial glycemia and risk of CVD, Jaakob Tuomilheto (Helsinki, Finland), one of the investigators of the DECODE study, discussed postchallenge glucose and the risk of CVD, presenting new analysis of this data. Normal glucose tolerance is associated with rapid first-phase insulin response, and the early defect in this step leads persons with IGT and, particularly, persons with type 2 diabetes to display postmeal hyperglycemia. The prevalence of asymptomatic diabetes is greater among men before age 60 years, and older persons frequently have postchallenge hyperglycemia. At lower levels of hyperglycemia, men with IGT tend to have higher fasting glucose levels, whereas women have higher postchallenge levels. Compared with persons previously known to have diabetes, there is a linear increase in mortality with increasing 2-h glucose, to a greater extent than that with fasting hyperglycemia. Comparing fasting glucose and 2-h glucose of normal, IGT, and type 2 diabetes, among men there is an increase in mortality with both increasing fasting and 2-h glucose levels, while among women the highest mortality is seen among those with both fasting and postload hyperglycemia. A similar pattern of increasing CVD mortality is seen with increasing 2-h glucose among men and among women, while fasting hyperglycemia is associated with lesser increase in mortality risk. Comparing mortality among persons with fasting glucose ≤6 vs. >6 mmol/l (108 mg/dl), adjustment for the 2-h glucose eliminates the mortality association of fasting hyperglycemia among men, but not among women, for whom, Tuomilheto stated, the fasting glucose remains a risk marker. The greatest absolute number of deaths is seen among persons with elevated 2-h glucose and normal fasting glucose levels because of the larger size of this subset, implying that if treatment is shown of benefit, then these individuals may comprise the most important group for intervention.
The systolic blood pressure is ∼15 mmHg higher in persons with postchallenge hyperglycemia than in those with normal postdchallenge glucose. Those persons in the DECODE dataset with diabetes and the lowest fasting glucose levels had the highest serum cholesterol, suggesting that the different components of the metabolic syndrome, dyslipidemia, and hyperglycemia may behave differently. Cigarette use is associated with increased CVD and total mortality, most notably among women with diabetes. Those women with diabetes who had hypercholesterolemia, hypertension, and obesity had the highest CVD mortality. Why, Tuomilheto asked, is postchallenge hyperglycemia producing such a great deal of increase in mortality? He suggested that even lower glucose levels than those currently used for defining diabetes are associated with increased mortality, and he also noted that hyperglycemia may produce a greater relative increase in mortality among women than among men.
The findings of the Workgroup on Outcomes of Hyperglycemia (also see http://diabeteshighlights.org/summary/june17.asp?sid=1) were described by Marian Rewers (Denver, CO). He noted that "postprandial" is not the same as "postoral glucose challenge," and represents "a simplification where we are measuring glucose 2 hours after a glucose load." The results of continuous glucose monitoring may be very interesting in that they more clearly show actual glucose levels encountered in persons at varying levels of risk. Further, he noted that plasma venous glucose levels are higher than the whole-blood levels measured in many settings. Thirty-one groups from around the world contributed to his data on all-cause and CVD mortality; these groups included the DECODE group, 11 U.S. studies, and studies of Pacific Island natives and Japanese persons. Participants were aged 45–84 years, and persons with diabetes taking insulin or oral medications were excluded; among 50,567 persons, there were 8,700 deaths. Based on the 2-h glucose, 18% of persons had IGT and 10% had diabetes; based on fasting glucose criteria, 12% had IFG and 6% diabetes. Europeans and Caucasian Americans were somewhat overrepresented in the study. All-cause mortality showed increase at both the lowest and highest deciles of fasting and 2-h glucose levels. For CVD mortality, rates were highest among those in the highest glucose groups. In review of the DECODE population, non-Hispanic whites in the U.S., and non-Caucasian populations, there was an increase in CVD mortality among persons diabetes defined with either fasting or 2-h glucose. The relative importance of hyperglycemia as a predictor of mortality was greater at younger than older ages. There is an effect of the 2-h glucose for any given fasting glucose level, while increasing fasting glucose did not affect mortality within a given 2-h glucose group.
Adjusting for cigarette use, blood pressure, BMI, lipids, age, sex, and ethnicity, with data available for 27,000 persons (of whom 3,700 died), with the fasting and 2-h glucose each divided into 6 categories, the 2nd to 6th deciles were compared with the 1st, 7th, 8th, 9th, and 10th deciles. Fasting glucose groups were ≤84, 85–100,101–104, 105–109, 110–125, and >126, respectively; the 2-h glucose was divided at cut points of 85, 101, 104, 110, 140, and 200 mg/dl. Persons with diabetes and those with fasting glucose ≤84 had the highest mortality. Even after adjusting for all of the CVD risk factors and for the 2-h glucose, those in the highest fasting glucose group remained at the highest risk. IFG adjusted for the 2-h glucose added little to the prediction of CVD mortality among Europeans, whereas diabetes, based on glucose >125 mg/dl, was a strong predictor. Looking at the 2-h glucose, those with the lowest 2-h glucose had low CVD risk. Those with 2-h glucose 140–169 had similar increase in mortality risk to that seen with 2-h glucose 170–199, and those with 2-h glucose <140 did not have increased risk, whereas CVD and total mortality were increased to an even greater extent in persons with diabetes based on 2-h glucose ≥200. The excess mortality risk related to diabetes was similar for patients diagnosed based on both fasting and 2-h glucose, while that for IGT was approximately one-third greater than that for IFG, and IGT predicted death independently of the fasting glucose, while IFG did not predict death independently of the 2-h glucose.
Rewers stated that he believed we need to be cautious in applying these data to treatment decisions, as we do not know whether hyperglycemia leads to CVD or whether glucose is simply a marker of at-risk groups, for which "manipulating the glucose per se" may not be the answer. Whether glucose tolerance testing should be used, and, if so, whether it should be used to find persons at high risk of CVD, or at high risk of diabetes, or with previously undetected diabetes, are further important policy questions.
Several presentations at the meeting added further information to these fascinating areas of uncertainty. Borenstein et al (891-P) reviewed 12 prospective and 2 cross-sectional studies of the association of postchallenge glucose with cardiovascular outcomes and all-cause mortality in type 2 diabetes, reporting that 12 studies documented a positive association and, of 7 studies comparing fasting and postchallenge glucose, 5 found the latter to have greater predictive power. Hunt et al (929-P) compared persons aged 45–64 years at enrollment in the San Antonio Heart Study who were followed at a mean of 7.7 years to determine whether diabetes had developed. A total of 1,038 had normal glucose tolerance and did not develop diabetes, and over an additional 7.7 years of follow-up, 152 deaths occurred, 70 of which were from CVD. Compared with those with normal glucose tolerance who did not develop diabetes, all-cause mortality was 1.5-, 1.02-, and 1.86-fold greater and CVD mortality was 2.13-, 1.16-, and 2.81-fold greater among 94 who had IGT and developed diabetes, 187 with IGT who did not develop diabetes, and 76 with normal glucose tolerance who developed diabetes, respectively. These data led the authors to suggest that it is diabetes per se that conveys increased risk.
Haffner et al. (919-P) compared glucose tolerance testing with the use of a predictive model incorporating BMI, blood pressure, fasting glucose and lipids, and medical history (28) using the Insulin Resistance Atherosclerosis Study database. Persons with IGT who met the Diabetes Prevention Project criteria for increased risk had a 37% 5-year incidence of diabetes as compared with 8% among those with normal glucose tolerance, but no increase in carotid intima-media thickness. Those in the highest vs. lower tertiles of the predictive model had a similar 32 vs. 8% diabetes risk but also showed carotid wall thickness of 856 vs 781 μm. Thus, the approach with multiple CVD risk factors is similarly effective in assessing diabetes risk, as shown in the initial study developed from the San Antonio Heart Study dataset, and was more effective (as might be expected) in identifying subclinical CVD.
In terms of treatment addressing the postprandial glucose among persons with diabetes, Abbasi et al (2449-PO) analyzed patients treated with diet alone, glipizide, metformin, or rosiglitazone. Fasting glucose showed strong correlation with the integrated glucose over 4 h following breakfast(r from 0.83 to 0.97) and a somewhat less strong correlation with average glucose during the 4 h following lunch (r from 0.69 to 0.90). Similarly, Agrawal et al. (372-P), who compared 71 persons receiving placebo with 64 receiving rosiglitazone 8 mg daily, showed a 47% decrease in the 4-h glucose area after a standard mixed meal, as well as a 25% decrease in fasting glucose. Thus, many treatments decrease both fasting and postprandial glucose. These observations may be treatment-dependent, however, as shown by a study by Baron et al. (376-P) of 58 and 83 type 2 diabetic persons receiving diet alone or metformin, respectively, with addition of nateglinide versus placebo. Blood glucose 2 h after breakfast decreased 44 and 49 mg/dl, while fasting glucose decreased 15 mg/dl in each group, suggesting that the 1.1 and 0.8% decreases in HbA1c with this agent was caused mainly by the decrease in postmeal glycemia. Interestingly, however, Carroll et al. (379-P) reported similar 32-mg/dl postprandial glucose-lowering effects of prebreakfast nateglinide and glipizide compared with placebo in 20 persons with type 2 diabetes. Reviewing another approach, Hanefeld (404-P) reported analysis of three studies of orlistat versus placebo in 372 versus 383 persons with type 2 diabetes, showing decrease in postprandial glucose of 29 vs. 2 mg/dl at 24 weeks.
Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Diabetes Center, Mount Sinai School of Medicine, New York, New York.
Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297, 1999
Smith NL, Savage PJ, Heckbert SR, Barzilay JI, Bittner VA, Kuller LH, Psaty BM: Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc 50:416–423, 2002
Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69–75, 1998
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893–2898, 1990
Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444, 1993
Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004–1010, 2002
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316:823–828, 1998
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22, 2002
Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335:217–225, 1996
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyerm H-M, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21:518–524, 1998
Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474–6479, 1997
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602, 1972
Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:1614–1619, 2001
Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ: Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38:421–428, 2001
Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515, 1997
Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Howard BV: Associations of insulin levels with left ventricular structure and function in American Indians: the Strong Heart Study. Diabetes 51:1543–1547, 2002
Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822–1826, 1997
Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 23:1236–1241, 2000
de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237–1241, 1995
DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617–621, 1999
Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050–1054, 1999
Liao D, Shofer JB, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care 24:39–44, 2001
Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583, 1996
Yano K, Grove JS, Reed DM, Chun HM: Determinants of the prognosis after a first myocardial infarction in a migrant Japanese population. The Honolulu Heart Program. Circulation 88:2582–2595, 1993
Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T: Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 17:835–840, 2000
Service FJ, Hall LD, Westland RE, O'Brien PC, Go VL, Haymond MW, Rizza RA: Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 25:316–321, 1983
Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581, 2002
Standards of Care Guidelines
© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.


Generally this error occurs with the fact that you have two networks configured with common name, but different passwords. And your Windows 10 PC identifies the same network by the same, but the password itself is changed, so it keeps trying to connect it.
Sometimes your Wi Fi would keep trying to connect, and won't even give you any wireless connection error. Following quick solution is perfect for you to solve both of these issues.
So we've found the cause – Two network SSID's are confliciting, so lets get rid of them, and connect to your wireless network freshly.
Click on Manage Wi-Fi Settings link at the bottom of your network lists.
Find the current network name you are trying to connect to. This list of wireless network connection is of all the networks you have connected so far, so it might be a long one.
In my case, I am trying to connect to wireless network named – 'Home'.
Click on this network name to expand options. And click on forget this network.
You're basically done cleaning the Wireless Connection memory that caused problem.
Go back to previous page, and click on your network name again.
Enter your network security key or password, and you will connect with your Wi-Fi network on Windows 10 instantly.
I hope this has solved your issue with Wi-Fi network on Windows 10, for more such tutorials, technology news & gadget reviews Join us on Facebook or follow me on twitter here @amolwagh.
Thank you Its work for me….. Thank again !!!
This doesn't work as not the root of my problem IMO. My home network uses WEP while the office uses WPA2. If I let Windows try to make the connect it doesn't correctly detect the authentication so asks for a username and password, rather than network key. If I use "Manually connect to a wireless network" option under the "set up a new network or connection" option, I can correctly set up the WEP connection. In previous versions of windows it would then make the connection. For some reason W10 doesn't proceed to make the manual connection.
What happens if you're trying to connect to a network you don't have listed?


text:
Reward of $100,000 to solve murder of Peter Beazley
Peter Beazley
A $100,000 reward is on offer for information leading to the arrest and conviction of those responsible for the death of Peter Beazley.
Mr Beazley, 39, was found dead in his home at Ambarvale in January 2002.
An inquest held in July 2006 by the Deputy State Coroner found that Mr Beazley had died from severe blunt trauma to the head.
But despite an extensive investigation the murder remains unsolved.
Detectives investigating the killing of Mr Beazley have conducted extensive inquiries but have now exhausted all leads.
Police believe there are people within the Ambarvale community with knowledge of the crime who have not come forward.
Murder of Peter Beazley


Leadership is performance. And nowhere is this more true than in public speaking. The most successful leaders have an intuitive sense of theater, performing many roles and convincing others to play their parts. Your senior executives will learn leadership as a performing art in The Genard Method's Voices of Leadership on-site training for management teams.
As an actor and communications expert, Dr. Gary Genard created his Method to pair the techniques of the theater with the latest research in neuroscience and leadership. Since 2001, he has been working with leaders and their teams in business, government, and NGOs worldwide. The Genard Method provides speakers in senior positions with the resources they need to communicate with an extraordinary level of poise, power, and professionalism.
Your team needs the ability to persuade and activate key stakeholders and "tough crowds," from employees to boards to external audiences. As C-suites expand and diversify, it's not enough to rely solely on a dynamic CEO. For true leadership development, your senior executives must also attain the highest level of competence and effectiveness as communicators.
"Your Voices of Leadership training was an extraordinary experience for our team. It was an eye-opening exercise in how we can speak strategically in our industry yet with a strong sense of performance. The Genard Method's theater-based approach is the perfect vehicle for this program. The exercises and simulations were invaluable in showing us how to get our key messages to resonate with different audiences. Everyone is talking about how much they appreciated your instruction, and are excited about their next opportunity to speak!"
Our Voices of Leadership program recalibrates your team's approach to public speaking by shifting your focus from content to performance. You will then learn how to access your natural talents to engage and persuade listeners. You'll discover how to boost your ability to tell your key audiences where you're going and how together you're going to get there.
Voices of Leadership is an intensive two-day on-site workshop for C-suite executives, senior management, association boards, and other leadership teams. The training maximizes your team's ability to speak with confidence and impact. Day One features group training and activities. Through dialogue, exercises, modeling of successful speakers, and presentation practice with feedback and critiques, you'll learn Dr. Genard's unique performance-based methods. The focus is on proven communication skills that embody and exemplify exceptional leadership.
Speaking under pressure and thinking on your feet.
Gaining buy-in and achieving consensus.
Formal presentations for high-stakes speaking events.
Body language and nonverbal communication.
Delivering bad news without losing credibility.
Handling resistance and tough Q & A.
Improving focus, mindfulness, and stage presence.
Day Two features 1:1 executive speech coaching with Dr. Genard. These one-hour intensive private sessions include further videotaped presentation practice, debriefing, and critiques. Issues of concern to each executive are covered, and sessions include simulated speaking situations. Voices of Leadership has a maximum of 5 participants. For larger groups, see our Speak at Your Best! corporate training program.
Develop your natural talents to speak for leadership.


In this series, FMC will outline false alarm by-laws for alarm response in cities in areas that FMC provides service and monitoring. We will present information if you have a security alarm system with security alarm monitoring, or if you have a fire alarm or sprinkler system monitored. Today, we will look at Alarm Response Policies in the City of Kingston.